Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Open to people ages 18 years and up

1. Measurable disease defined as ≥1 measurable nodal lesion (long axis >1.5 cm and short axis >1.0 cm) or ≥1 measurable extra-nodal lesion (long axis >1.0 cm) on computed tomography (CT) or magnetic resonance imaging (MRI)
2. Eastern Cooperative Oncology Group (ECOG) PS score of 0, 1 or 2
3. Acceptable organ function at screening
4. CD20-positive non-Hodgkin lymphoma (NHL) at most recent representative tumor biopsy
5. If of childbearing potential subject must practicing a highly effective method of birth control

6. A man who is sexually active with a woman of childbearing potential must agree to use a barrier method of birth control

   Arm 1:

7. Newly Diagnosed Documented diffuse large B-cell lymphoma (DLBCL)
8. DLBCL, NOS
9. "double-hit" or "triple-hit" DLBCL

10. FL Grade 3B

    Arm 2: R/R FL Arm 3: Newly diagnosed, previously untreated FL grade 1-3A Arm 4:

11. Documented DLBCL and eligible for HDT-ASCT
12. DLBCL, NOS
13. "double-hit" or "triple-hit" DLBCL

14. FL Grade 3B

    Arm 5:

15. Relapsed or refractory documented DLBCL and ineligible for HDT-ASCT
16. DLBCL, NOS
17. "double-hit" or "triple-hit" DLBCL

18. FL Grade 3B

    Arm 6: Newly diagnosed, previously untreated FL grade 1-3A Arm 7:

19. FL Grade 1-3A

20. If PR or CR per Lugano criteria following first-line or second-line treatment with SOC regimen, and last dose of SOC within 6 months prior to enrollment.

    Arm 8:

21. DLBCL, NOS
22. T-cell/histiocyte rich DLBCL
23. "double-hit" or "triple-hit" DLBCL

24. FL Grade 3B

    Arm 9:

25. R/R FL

26. Progressed within 24 months of initiating first-line treatment

    Arm 10:

27. Documented DLBCL and eligible for HDT-ASCT
28. DLBCL, NOS
29. "double-hit" or "triple-hit" DLBCL
30. FL Grade 3B

1. Chemotherapy, radiation therapy, or major surgery within 4 weeks prior to the first dose of epcoritamab
2. Any prior treatment with a bispecific antibody targeting CD3 and CD20.
3. Treatment with CAR-T therapy within 30 days prior to first dose of epcoritamab
4. Clinically significant cardiovascular disease
5. Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
6. CNS lymphoma or known CNS involvement by lymphoma at screening as confirmed by MRI/CT scan of the brain and, if clinically indicated, by lumbar puncture
7. Active positive tests for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
8. Known history of seropositivity of human immunodeficiency virus (HIV)

9. Active tuberculosis or history of completed treatment for active tuberculosis within the past 12 months

   10. Neuropathy > grade 1 11. Receiving immunostimulatory agent 12. Prior allogeneic HSCT 13. Current seizure disorder requiring anti-epileptic therapy NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.